Day One Biopharmaceuticals Income Statement (2022-2025) | DAWN

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 8.19M93.76M29.21M30.76M33.91M39.80M
Operating items
Research & Development 27.83M33.16M37.35M40.21M92.11M33.56M61.82M39.62M36.15M31.42M
Selling, General & Administrative 18.03M18.27M22.17M26.56M30.19M28.97M29.73M29.32M28.97M28.15M
Other Operating Expenses 0.71M1.59M2.98M2.88M3.77M4.48M
Operating Expenses 45.85M51.44M59.52M66.77M123.00M64.12M94.54M71.83M68.88M64.05M
Operating Income -45.85M-51.44M-59.52M-66.77M-114.81M29.64M-65.33M-41.07M-34.97M-24.25M
EBIT -45.85M-51.44M-59.52M-66.77M-114.81M29.64M-65.33M-41.07M-34.97M-24.25M
Non-operating items
Interest & Investment Income 3.47M5.29M5.02M4.37M3.96M5.32M6.05M5.09M4.67M4.56M
Other Non Operating Income -0.00M-0.00M-0.02M-0.01M-0.01M1.20M0.04M-0.02M-0.02M-0.03M
Non Operating Income 3.46M5.29M5.01M4.36M111.95M6.52M6.09M5.07M4.65M4.53M
Net income details
EBT -42.39M-46.15M-54.49M-62.40M-110.84M34.96M-59.28M-35.97M-30.30M-19.69M
Tax Provisions 1.55M-0.88M6.44M
Profit After Tax -42.39M-46.15M-54.51M-62.41M-4.41M37.04M-65.71M-36.00M-30.32M-19.73M
Income from Non-Controlling Interests 42.39M46.15M54.51M62.41M2.85M-36.16M59.24M36.00M30.32M19.73M
Income from Continuing Operations -42.39M-46.15M-54.49M-62.40M-112.40M35.84M-65.72M-35.97M-30.30M-19.69M
Consolidated Net Income -42.39M-46.15M-54.49M-62.40M-112.40M35.84M-65.72M-35.97M-30.30M-19.69M
Income towards Parent Company -42.39M-46.15M-54.49M-62.40M-112.40M35.84M-65.72M-35.97M-30.30M-19.69M
Net Income towards Common Stockholders -42.39M-46.15M-54.49M-62.40M-112.40M35.84M-65.72M-35.97M-30.30M-19.69M
Additional items
EPS (Basic) -0.59-0.54-0.64-0.72-0.050.38-0.69-0.35-0.29-0.19
EPS (Weighted Average and Diluted) -0.59-0.54-0.64-0.72-0.050.38-0.69-0.35-0.29-0.19
Shares Outstanding (Weighted Average) 61.95M61.91M73.46M73.55M73.59M73.57M86.97M87.04M87.38M87.39M87.76M100.85M101.35M101.36M102.43M
Shares Outstanding (Diluted Average) 58.38M60.76M71.01M65.47M71.97M74.96M85.95M79.77M86.68M87.12M96.94M93.23M102.71M103.07M103.38M
EBITDA -45.85M-51.44M-59.52M-66.77M-114.81M29.64M-65.33M-41.07M-34.97M-24.25M